Selective Targeting of Immune Checkpoints HLA‐G and CD47 Using Novel Dual Signaling Protein DSP216 Promotes Innate Anticancer Immunity

ABSTRACT Immunotherapy has significantly improved treatment outcomes for cancer patients within the past decade, with breakthrough results using immune checkpoint inhibitors (ICIs), most notably those targeting the PD‐1/PD‐L1 inhibitory axis. Nevertheless, many patients and tumor types do not respon...

Descrición completa

Detalles Bibliográficos

Principais autores:	Lisa J. Jacob, Liat Tamir, Mufeed Abdeen, Ami Tamir, Alexandra Aronin, Itai Bloch, Roy Kahn, Iris Pecker, Mark Tykocinski, Gerwin Huls, Yaron Pereg, Ayelet Chajut, Edwin Bremer
Formato:	Artigo
Idioma:	Inglês
Publicado:	Wiley 2026-06-01
Series:	Advanced Science
Assuntos:	CD47 HLA‐G immune checkpoints immunotherapy LILRB1 LILRB2
Acceso en liña:	https://doi.org/10.1002/advs.202521448
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!